Experimental combo aims to tackle stubborn colorectal cancer
NCT ID NCT07147231
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times
Summary
This trial is testing whether combining pidnarulex (a drug that blocks cancer cell growth) with cemiplimab (an immunotherapy that helps the immune system attack cancer) is safe and effective for people with advanced colorectal cancer that no longer responds to standard treatments. The study has two phases: first, finding the best dose of pidnarulex, then comparing the combination against pidnarulex alone in 86 participants. It focuses on a specific type called microsatellite stable (MSS) colorectal cancer, which is harder to treat.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pidnarulex (CX-5461) and cemiplimab (Libtayo)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced colorectal cancer that hasn't responded to other therapies.
- What could go wrong
- This is an early-phase trial (phase 1/2) with a small number of participants, so the combination may not prove effective or safe enough for wider use. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory Saint Joseph's Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
-
MedStar Georgetown University Hospital
RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
University of Maryland/Greenebaum Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new blood test spot colorectal cancer return earlier?
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?